Rovi’s injectables CDMO rebrands as Rois and acquires BMS facility
Gains US-based operations with its new Phoenix, Arizona injectable drug product manufacturing and packaging site.
List view / Grid view
Gains US-based operations with its new Phoenix, Arizona injectable drug product manufacturing and packaging site.
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
Once completed, the Berlin site will also be the new home for one of the company’s Bayer Co. Lab start-up incubators.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
The CDMO’s new site will support its work in cell and gene therapy.